Prime Medicine (PRME) Current Deferred Revenue (2024 - 2026)

Prime Medicine (PRME) has 3 years of Current Deferred Revenue data on file, last reported at $7.3 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue fell 10.88% year-over-year to $7.3 million; the trailing twelve-month figure through Mar 2026 stood at $7.3 million (down 10.88% YoY), and the FY2025 full-year result was $7.8 million, up 10.32% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $7.3 million, down from $7.8 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $9.3 million in Q3 2024 and bottomed at $7.0 million in Q3 2025.
• The 3-year median for Current Deferred Revenue is $7.8 million (2025), against an average of $7.9 million.
• Peak annual rise in Current Deferred Revenue reached 10.32% in 2025, while the deepest fall reached 25.1% in 2025.
• A 3-year view of Current Deferred Revenue shows it stood at $7.1 million in 2024, then advanced by 10.32% to $7.8 million in 2025, then slipped by 6.44% to $7.3 million in 2026.
• The last three Current Deferred Revenue figures came in at $7.3 million (Q1 2026), $7.8 million (Q4 2025), and $7.0 million (Q3 2025), per Business Quant data.

Peer Comparison